This phase II trial studies how well artificial tears works in reducing radioiodine levels in the nasolacrimal duct system in patients with thyroid carcinoma following radioiodine therapy. Radioactive iodine therapy for thyroid carcinoma has been associated with nasolacrimal duct obstruction. Artificial tears may dilute the amount of radioactive iodine in the tears of the eyes, thus decreasing uptake by the cells lining the nasolacrimal duct system.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04327999.
PRIMARY OBJECTIVE:
I. To assess whether use of preservative free artificial tears following radioactive iodine administration will lower the level of radioactive iodine in the tears of patients treated with radioactive iodine for thyroid carcinoma.
SECONDARY OBJECTIVE:
I. To deduce whether artificial tears would be an effective preventative intervention to decrease the risk of developing nasolacrimal duct stenosis, which has been associated with radioactive iodine administration.
OUTLINE:
Patients administer artificial tears into their right contact-wearing eye every 15 minutes for 2 hours then every 30 minutes for 4 hours on day 1, once every 1 hour for 12 hours on day 2, four times on day 3, and twice on day 4 in the absence of unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 week, then every 6 months for 2 years.
Lead OrganizationVanderbilt University/Ingram Cancer Center
Principal InvestigatorRachel Sobel
